S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
Log in
NYSE:HAE

Haemonetics Stock Forecast, Price & News

$119.12
-4.05 (-3.29 %)
(As of 01/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$118.89
Now: $119.12
$123.78
50-Day Range
$115.06
MA: $121.01
$129.03
52-Week Range
$63.41
Now: $119.12
$129.92
Volume497,552 shs
Average Volume406,625 shs
Market Capitalization$6.05 billion
P/E Ratio57.55
Dividend YieldN/A
Beta0.56
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Haemonetics logo

MarketRank

Overall MarketRank

1.63 out of 5 stars

Medical Sector

277th out of 1,925 stocks

Surgical & Medical Instruments Industry

27th out of 169 stocks

Analyst Opinion: 2.4Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
CUSIP40502410
Phone781-848-7100
Employees3,004
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$988.48 million
Cash Flow$5.27 per share
Book Value$11.67 per share

Profitability

Net Income$76.53 million

Miscellaneous

Market Cap$6.05 billion
Next Earnings Date2/2/2021 (Confirmed)
OptionableOptionable
$119.12
-4.05 (-3.29 %)
(As of 01/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HAE News and Ratings via Email

Sign-up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Haemonetics (NYSE:HAE) Frequently Asked Questions

How has Haemonetics' stock price been impacted by Coronavirus?

Haemonetics' stock was trading at $103.72 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, HAE shares have increased by 14.8% and is now trading at $119.12.
View which stocks have been most impacted by COVID-19
.

Is Haemonetics a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Haemonetics stock.
View analyst ratings for Haemonetics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Haemonetics?

Wall Street analysts have given Haemonetics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Haemonetics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Christopher Simon's approval rating as Haemonetics' CEO?

48 employees have rated Haemonetics CEO Christopher Simon on Glassdoor.com. Christopher Simon has an approval rating of 63% among Haemonetics' employees. This puts Christopher Simon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Haemonetics' next earnings date?

Haemonetics is scheduled to release its next quarterly earnings announcement on Tuesday, February 2nd 2021.
View our earnings forecast for Haemonetics
.

How can I listen to Haemonetics' earnings call?

Haemonetics will be holding an earnings conference call on Tuesday, February 2nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Haemonetics' earnings last quarter?

Haemonetics Co. (NYSE:HAE) announced its quarterly earnings results on Wednesday, November, 4th. The medical instruments supplier reported $0.62 EPS for the quarter, topping the consensus estimate of $0.51 by $0.11. The medical instruments supplier had revenue of $209.50 million for the quarter, compared to analyst estimates of $207.66 million. Haemonetics had a trailing twelve-month return on equity of 22.85% and a net margin of 11.76%. Haemonetics's quarterly revenue was down 17.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.72 earnings per share.
View Haemonetics' earnings history
.

What price target have analysts set for HAE?

5 analysts have issued 1-year price targets for Haemonetics' stock. Their forecasts range from $106.00 to $142.00. On average, they expect Haemonetics' share price to reach $132.40 in the next twelve months. This suggests a possible upside of 11.1% from the stock's current price.
View analysts' price targets for Haemonetics
or view Wall Street analyst' top-rated stocks.

Who are some of Haemonetics' key competitors?

What other stocks do shareholders of Haemonetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), AbbVie (ABBV), Citigroup (C), Align Technology (ALGN), (APA), Chipotle Mexican Grill (CMG), Netflix (NFLX) and Pfizer (PFE).

Who are Haemonetics' key executives?

Haemonetics' management team includes the following people:
  • Mr. Christopher A. Simon, CEO, Pres & Director (Age 57, Pay $2.53M)
  • Mr. William P. Burke, CFO & Exec. VP (Age 53, Pay $1.1M)
  • Ms. Michelle L. Basil, Exec. VP, Gen. Counsel & Sec. (Age 49, Pay $968.85k)
  • Ms. Jacqueline D. Scanlan, Sr. VP of HR (Age 48, Pay $792.1k)
  • Mr. Josep Lluis Llorens, Sr. VP of Global Manufacturing & Supply Chain (Age 59, Pay $826.89k)
  • Mr. Dan Goldstein, Principal Accounting Officer, VP & Corp. Controller (Age 44)
  • Ms. Anila Lingamneni, Exec. VP & Chief Technology Officer (Age 54)
  • Ms. Olga Guyette, Director of Investor Relations
  • Carla Burigatto, VP of Communications
  • Mr. Francis Tan, Sr. VP of Corp. Devel. & Planning

What is Haemonetics' stock symbol?

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

Who are Haemonetics' major shareholders?

Haemonetics' stock is owned by a variety of retail and institutional investors. Top institutional investors include KAMES CAPITAL plc (0.78%), Boston Trust Walden Corp (0.50%), Summit Creek Advisors LLC (0.24%), New York State Teachers Retirement System (0.12%), Janney Montgomery Scott LLC (0.04%) and State of Alaska Department of Revenue (0.02%). Company insiders that own Haemonetics stock include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Mark W Kroll, Michelle L Basil, Ronald G Gelbman, Said Bolorforosh and William P Mr Burke.
View institutional ownership trends for Haemonetics
.

Which institutional investors are selling Haemonetics stock?

HAE stock was sold by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC, Pacer Advisors Inc., KAMES CAPITAL plc, Janney Montgomery Scott LLC, New York State Teachers Retirement System, State of Alaska Department of Revenue, and Crossmark Global Holdings Inc.. Company insiders that have sold Haemonetics company stock in the last year include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Mark W Kroll, Michelle L Basil, and William P Mr Burke.
View insider buying and selling activity for Haemonetics
or view top insider-selling stocks.

Which institutional investors are buying Haemonetics stock?

HAE stock was acquired by a variety of institutional investors in the last quarter, including Rowland Carmichael Advisors Inc. ADV, First Hawaiian Bank, Wealth Alliance Advisory Group LLC, First Citizens Bank & Trust Co., WBH Advisory Inc., 6 Meridian, IBM Retirement Fund, and IFP Advisors Inc.
View insider buying and selling activity for Haemonetics
or or view top insider-buying stocks.

How do I buy shares of Haemonetics?

Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Haemonetics' stock price today?

One share of HAE stock can currently be purchased for approximately $119.12.

How big of a company is Haemonetics?

Haemonetics has a market capitalization of $6.05 billion and generates $988.48 million in revenue each year. The medical instruments supplier earns $76.53 million in net income (profit) each year or $3.31 on an earnings per share basis. Haemonetics employs 3,004 workers across the globe.

What is Haemonetics' official website?

The official website for Haemonetics is www.haemonetics.com.

How can I contact Haemonetics?

Haemonetics' mailing address is 125 Summer Street, Boston MA, 02110. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.